Methods and compositions for the treatment of melanoma
Provided herein are methods and compositions for the treatment of melanoma using anti-tumor immune cells treated with a PTD-MYC fusion protein (e.g., an HIV TAT-MYC fusion protein).
1. A composition comprising:
(a) a MYC fusion peptide, comprising (i) a protein transduction domain; (ii) a MYC polypeptide sequence, wherein the MYC fusion peptide comprises SEQ ID NO: 1; and
(b) one or more primary immune cells from a donor subject that has a melanoma tumor, wherein the one or more primary immune cells are reactive against a melanoma-specific antigen.
2. The composition of claim 1 , wherein the protein transduction domain sequence is a TAT protein transduction domain sequence.
3. The composition of claim 1 , wherein the one or more immune cells comprises a T cell, a B cell, an NK cell, or any combination thereof.
4. The composition of claim 1 , wherein the one or more immune cells comprises a tumor-infiltrating lymphocyte, T-cell receptor modified lymphocyte, or a chimeric antigen receptor modified lymphocyte.
5. The composition of claim 4 , wherein the tumor-infiltrating lymphocyte has a CD8+CD25+ signature or a CD4+CD25+ signature.